tradingkey.logo

Co-Diagnostics Inc

CODX
查看詳細走勢圖
0.235USD
-0.006-2.41%
收盤 12/26, 16:00美東報價延遲15分鐘
11.31M總市值
虧損本益比TTM

Co-Diagnostics Inc

0.235
-0.006-2.41%
盤中分時
1分
30分
1小時
日k
週k
月k
日k

今天

-2.41%

5天

-10.95%

1月

-37.05%

6月

-11.95%

今年開始到現在

-68.67%

1年

-69.01%

查看詳細走勢圖

TradingKey Co-Diagnostics Inc股票評分

單位: USD 更新時間: 2025-12-26

操作建議

Co-Diagnostics Inc當前公司基本面數據相對非常健康,增長潛力穩定。當前估值合理,在醫療設備與耗材行業排名128/207位。機構持股佔比非常高,近一個月多位分析師給出公司評級為買入。最高目標價1.25。中期看,股價處於下降通道。近一個月,市場表現非常差,但技術面評分較高。目前股價在壓力位和支撐位之間,可以做區間波段操作。

Co-Diagnostics Inc評分

相關信息

行業排名
128 / 207
全市場排名
327 / 4563
所屬行業
醫療設備與耗材

壓力支撐

由於公司未披露,未能獲取相關數據

多維評測

本期評分
上期評分

分析師目標

基於 2 分析師
買入
評級
1.250
目標均價
+260.33%
漲幅空間
數據免責聲明:分析師評級與目標價由LSEG提供,僅供參考,不應當作投資建議

Co-Diagnostics Inc亮點

亮點風險
Co-Diagnostics, Inc. is a molecular diagnostics company, which develops, manufactures and markets diagnostics technologies. The Company’s technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious disease. Its diagnostics systems enable dependable, low-cost, molecular testing for organisms and genetic diseases by automating or simplifying historically complex procedures in both the development and administration of tests. It is developing a portable diagnostic device and test system designed for point-of-care and at-home use. The system consists of its PCR instrument that it refers to as the Co-Dx PCR Pro instrument, its proprietary diagnostic test cup system and a mobile application to be installed on the user’s mobile device.
業績增長期
公司處於發展階段,最新年度總收入3.92M美元
利潤高增長
公司淨利潤處於行業前列,最新年度總收入3.92M美元
估值高估
公司最新PE估值-0.24,處於3年歷史高位
機構減倉
最新機構持股11.14M股,環比減少2.69%
詹姆斯·西蒙斯持倉
明星投資者詹姆斯·西蒙斯持倉,最新持倉867.52K股
活躍度增加
近期活躍度增加,過去20天平均換手率10.46

Co-Diagnostics Inc新聞

即將為您帶來更多新聞,敬請期待。 。 。

財務指標

每股收益

由於公司未披露,未能獲取相關數據

營業總收入

由於公司未披露,未能獲取相關數據

Co-Diagnostics Inc簡介

Co-Diagnostics, Inc. is a molecular diagnostics company, which develops, manufactures and markets diagnostics technologies. The Company’s technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious disease. Its diagnostics systems enable dependable, low-cost, molecular testing for organisms and genetic diseases by automating or simplifying historically complex procedures in both the development and administration of tests. It is developing a portable diagnostic device and test system designed for point-of-care and at-home use. The system consists of its PCR instrument that it refers to as the Co-Dx PCR Pro instrument, its proprietary diagnostic test cup system and a mobile application to be installed on the user’s mobile device.
公司代碼CODX
公司Co-Diagnostics Inc
CEOEgan (Dwight H)
網址https://codiagnostics.com/

常見問題

Co-Diagnostics Inc(CODX)的當前股價是多少?

Co-Diagnostics Inc(CODX)的當前股價是 0.235。

Co-Diagnostics Inc 的股票代碼是什麼?

Co-Diagnostics Inc的股票代碼是CODX。

Co-Diagnostics Inc股票的52週最高點是多少?

Co-Diagnostics Inc股票的52週最高點是1.550。

Co-Diagnostics Inc股票的52週最低點是多少?

Co-Diagnostics Inc股票的52週最低點是0.228。

Co-Diagnostics Inc的市值是多少?

Co-Diagnostics Inc的市值是11.31M。

Co-Diagnostics Inc的淨利潤是多少?

Co-Diagnostics Inc的淨利潤為-37.64M。

現在Co-Diagnostics Inc(CODX)的股票是買入、持有還是賣出?

根據分析師評級,Co-Diagnostics Inc(CODX)的總體評級為買入,目標價格為1.250。

Co-Diagnostics Inc(CODX)股票的每股收益(EPS TTM)是多少

Co-Diagnostics Inc(CODX)股票的每股收益(EPS TTM)是-0.974。
KeyAI